The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
September 09 2008 - 9:20AM
PR Newswire (US)
TUSTIN, Calif., Sept. 9 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a leading vertically
integrated bio-pharmaceutical company with major operations in
China and the US, today announced that The Wall Street Transcript
(http://www.twst.com/) features an interview with Mr. Gary Dreher,
President and CEO of AMDL, Inc., in its Healthcare Services report
for September 9, 2008. A copy of the interview is available in the
Healthcare Services section of The Wall Street Transcript located
at http://www.twst.com/ . In the interview, Mr. Dreher discusses
AMDL's focus on the $100B China market and the Company's
distribution expansion throughout the region. Additionally, he
covers the AMDL's breakthrough DR-70(R) ELISA (FDP) cancer
diagnostic test kit, which was recently cleared by the US FDA for
the monitoring of colorectal cancer; as well as the company's
top-selling products developed through its wholly owned subsidiary
Jade Pharmaceuticals. According to Mr. Dreher, "AMDL is a growth
company with significant potential and a key priority for the
Company is effectively communicating our story to existing and
potential investors. This interview provided us with a perfect
opportunity to outline our current market environment, recent
business developments, and ongoing goals and strategies in a
straightforward and candid way for the investment community and we
are excited to be featured." The Wall Street Transcript (TWST)
conducts in-depth interviews of CEOs of public companies to provide
an unscripted, first-hand perspective for TWST subscribers, which
includes mutual fund managers, research analysts, money managers,
investment brokers and individual investors. AMDL's interview with
The Wall Street Transcript is published and available to the public
immediately. To view this interview visit http://www.twst.com/.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. AMDL, together with Jade, engages
in the development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products. About Jade Pharmaceuticals
Inc.: JPI has access to the fastest growing pharmaceutical and
consumer market in the world: China. AMDL, through its Jade
subsidiaries, currently holds licenses for 133 products that are
manufactured as large volume injection fluids, tablets and other
related products. It currently manufactures over 20 key generic,
over-the-counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
Forward-looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
AMDL Contact: Kristine Szarkowitz Director-Investor Relations (M)
(206) 310-5323 DATASOURCE: AMDL, Inc. CONTACT: Kristine Szarkowitz,
Director-Investor Relations of AMDL, Inc., +1-206-310-5323, Web
site: http://www.twst.com/ http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024